{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:20:03Z","timestamp":1763702403828,"version":"3.45.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the diagnostic performance of APOA4, CEACAM1, CD147, DJ-1\/PARK7, Gamma-synuclein, S100A1, and Stathmin-1 in urothelial carcinoma and establish optimal immunohistochemical cutoffs for their use as diagnostic markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This cross-sectional study included 141 histologically confirmed urothelial carcinoma cases and controls. Immunohistochemical staining was optimized for each biomarker, and semiquantitative scoring was applied. Diagnostic validity was assessed using receiver operating characteristic (ROC) analysis, comparing sensitivity and specificity across several cutoffs and biomarker panels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among seven biomarkers, APOA4, DJ-1\/PARK7, Gamma-synuclein, and Stathmin-1 demonstrated high diagnostic accuracy (\u226580% sensitivity and specificity). Using an Allred score \u22642 as a cutoff, the sensitivity\/specificity were as follows: APOA4, 96%\/100%; DJ-1\/PARK7, 97%\/94%; Gamma-synuclein, 98%\/84%; and Stathmin-1, 98%\/90%. A combined panel of these four biomarkers achieved near-perfect diagnostic performance, reaching almost 100% sensitivity and specificity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A biomarker panel comprising Stathmin-1, DJ-1\/PARK7, Gamma-synuclein, and APOA4 reliably distinguished urothelial carcinoma from benign urothelium. These markers, when integrated with cytology, could enhance the diagnostic precision and reduce dependence on invasive cystoscopy. The proposed cutoffs (10%\u201320% positive cells or Allred score \u22642) offer clinically actionable threshold for histopathological practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1587558","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:15:05Z","timestamp":1763702105000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of expression profiles of APOA4, CEACAM1, CD147, DJ-1\/PARK7, Gamma-synuclein, S100A1, and Stathmin-1 in urothelial carcinomas using immunohistochemical assays"],"prefix":"10.3389","volume":"15","author":[{"given":"Naveed","family":"Sharif","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walayat","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asif","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taj","family":"Ali Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umar","family":"Nishan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussah M.","family":"Alobaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sher Zaman","family":"Safi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed A. A.","family":"Rizv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nawshad","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: An overview","volume":"149","author":"Ferlay","year":"2021","journal-title":"Int J cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s44197-023-00104-5","article-title":"Exploring the burden of cancer in Pakistan: an analysis of 2019 data","volume":"13","author":"Tufail","year":"2023","journal-title":"J Epidemiol Global Health"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur urology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2020.01.007","article-title":"Management of muscle-invasive bladder cancer in the 2020s: challenges and perspectives","volume":"6","author":"Gakis","year":"2020","journal-title":"Eur Urol Focus"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3390\/cancers13061396","article-title":"Imaging and management of bladder cancer","volume":"13","author":"Wong","year":"2021","journal-title":"Cancers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-82048-0_9","article-title":"Urine cytology in the clinical management of bladder cancer","author":"Gabrielson","year":"2021","journal-title":"Compr Diagn Approach to Bladder Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.04.059","article-title":"An international collaborative consensus statement on en bloc resection of bladder tumour incorporating two systematic reviews, a two-round Delphi survey, and a consensus meeting","volume":"78","author":"Teoh","year":"2020","journal-title":"Eur urology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-20-1990","article-title":"Review of non-invasive urinary biomarkers in bladder cancer","volume":"9","author":"Lee","year":"2020","journal-title":"Trans Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/etm.2021.10205","article-title":"Tumoral markers in bladder cancer","volume":"22","author":"Bratu","year":"2021","journal-title":"Exp Ther Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-022-04253-3","article-title":"Urinary biomarkers for bladder cancer diagnosis and NMIBC follow-up: A systematic review","volume":"41","author":"Soorojebally","year":"2023","journal-title":"World J Urology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur urology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3233\/BLC-160054","article-title":"A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder cancer","volume":"2","author":"D\u2019Costa","year":"2016","journal-title":"Bladder Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur urology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.3390\/diagnostics12123093","article-title":"Allred scoring of ER-IHC stained whole-slide images for hormone receptor status in breast carcinoma","volume":"12","author":"Ahmad Fauzi","year":"2022","journal-title":"Diagnostics"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.29271\/jcpsp.2023.06.625","article-title":"National cancer registry of Pakistan: first comprehensive report of cancer statistics 2015-2019","volume":"33","author":"Ikram","year":"2023","journal-title":"J Coll Physicians Surgeons\u2013Pakistan: JCPSP"},{"key":"B17","doi-asserted-by":"publisher","first-page":"13539","DOI":"10.18632\/oncotarget.3841","article-title":"Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma","volume":"6","author":"Kumar","year":"2015","journal-title":"Oncotarget"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.06.051","article-title":"Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy","volume":"186","author":"Wosnitzer","year":"2011","journal-title":"J urology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.14218\/JCTP.2022.00035","article-title":"The Paris System for Reporting Urinary Cytology: an updated review","volume":"3","author":"Chen","year":"2023","journal-title":"J Clin Trans Pathology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3390\/medicina57080749","article-title":"Bladder cancer: current challenges and future directions","volume":"57","author":"Dobruch","year":"2021","journal-title":"Medicina"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001305","article-title":"A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy","volume":"204","author":"Mori","year":"2020","journal-title":"J urology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"705","DOI":"10.12669\/pjms.36.4.1638","article-title":"Diagnostic accuracy of NMP 22 and urine cytology for detection of transitional cell carcinoma urinary bladder taking cystoscopy as gold standard","volume":"36","author":"Sajid","year":"2020","journal-title":"Pakistan J Med Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.22465\/juo.234600040002","article-title":"Bladder cancer in South Korea: analysis of trends and risk factors of bladder cancer in south Korea using a nationwide database","volume":"21","author":"Yoo","year":"2023","journal-title":"J Urologic Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medsci8010015","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27330","article-title":"A review of the etiology and epidemiology of bladder cancer: All you need to know","volume":"14","author":"Halaseh","year":"2022","journal-title":"Cureus"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.3390\/ijerph18105237","article-title":"Survival and characteristics of bladder cancer: analysis of the Malaysian National Cancer Registry","volume":"18","author":"Nik Ab Kadir","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"B27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/2051415819872910","article-title":"Impact of the 2015 NICE guidance for urgent assessment of patients with non-visible haematuria","volume":"13","author":"John","year":"2020","journal-title":"J Clin Urology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.18203\/2349-2902.isj20205823","article-title":"Incidence of various urothelial Malignancy in patients undergoing transurethral resection of bladder tumour in tertiary care hospital","volume":"8","author":"Kaur","year":"2021","journal-title":"Int Surg J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000000525","article-title":"Fluid intake and clinicopathological characteristics of bladder cancer: the West Midlands Bladder Cancer Prognosis Programme","volume":"29","author":"van Hensbergen","year":"2020","journal-title":"Eur J Cancer Prev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.252.225","article-title":"Urine lactoferrin as a potential biomarker reflecting the degree of Malignancy in urothelial carcinoma of the bladder","volume":"252","author":"Matsumura","year":"2020","journal-title":"Tohoku J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3147","article-title":"Prognostic values of the clinicopathological characteristics and survival outcomes in micropapillary urothelial carcinoma of the bladder: A SEER database analysis","volume":"9","author":"Jin","year":"2020","journal-title":"Cancer Med"},{"key":"B32","first-page":"41.e1","article-title":"Functional genetic variant of WW domain containing oxidoreductase gene associated with urothelial cell carcinoma clinicopathologic characteristics and long-term survival","volume-title":"Urol Oncol.","author":"Hung","year":"2020"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.864156","article-title":"SUMOylation pattern predicts prognosis and indicates tumor microenvironment infiltration characterization in bladder cancer","volume":"13","author":"Xia","year":"2022","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract13040073","article-title":"Clinico-pathological features and immunohistochemical comparison of p16, p53, and Ki-67 expression in muscle-invasive and non-muscle-invasive conventional urothelial bladder carcinoma","volume":"13","author":"Hasan","year":"2023","journal-title":"Clinics Practice"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.771036","article-title":"Prognostic value of vascular-expressed PSMA and CD248 in urothelial carcinoma of the bladder","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33425\/2639-944X.1119","article-title":"Diagnostic value of urine cytology for detection of bladder cancer","volume":"4","author":"Seputra","year":"2020","journal-title":"J Med-Clin Res Rev"},{"key":"B37","first-page":"384","article-title":"Performance characteristics of urinary cytology in patients presenting with gross and microscopic hematuria","volume":"9","author":"Pan","year":"2021","journal-title":"Am J Clin Exp Urology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2014.03.031","article-title":"Prognostic significance of lactate\/proton symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder","volume":"84","author":"Choi","year":"2014","journal-title":"Urology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/mc.22222","article-title":"CD147 and MCT1-potential partners in bladder cancer aggressiveness and cisplatin resistance","volume":"54","author":"Afonso","year":"2015","journal-title":"Mol carcinogenesis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7638975","article-title":"CD147 expression is associated with tumor proliferation in bladder cancer via GSDMD","volume":"2020","author":"Peng","year":"2020","journal-title":"BioMed Res Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.05.040","article-title":"CEACAM1: a novel urinary marker for bladder cancer detection","volume":"57","author":"Tilki","year":"2010","journal-title":"Eur urology"},{"key":"B42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1159\/000368166","article-title":"Panel of urinary diagnostic markers for non-invasive detection of primary and recurrent urothelial urinary bladder carcinoma","volume":"95","author":"Soukup","year":"2015","journal-title":"Urol internationalis"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12894-020-00759-3","article-title":"The role of antibody expression and their association with bladder cancer recurrence: a single-centre prospective clinical-pilot study in 35 patients","volume":"20","author":"Ella-Tongwiis","year":"2020","journal-title":"BMC urology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.14670\/HH-22.1025","article-title":"The S100 proteins for screening and prognostic grading of bladder cancer","volume":"22","author":"Yao","year":"2007","journal-title":"Histol histopathology"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2012.05.005","article-title":"Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder","volume":"413","author":"Bhagirath","year":"2012","journal-title":"Clinica chimica Acta"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.427","article-title":"The prognostic value and therapeutic target role of stathmin-1 in urinary bladder cancer","volume":"111","author":"Hemdan","year":"2014","journal-title":"Br J cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2019_190124N74","article-title":"The significance of calprotectin, CD147, APOA4 and DJ-1 in non-invasive detection of urinary bladder carcinoma","volume":"66","author":"Soukup","year":"2019","journal-title":"Neoplasma"},{"key":"B48","doi-asserted-by":"publisher","first-page":"4848752","DOI":"10.1155\/2020\/4848752","article-title":"The dependence between urinary levels of angiogenesis factors, 8-iso-prostaglandin F2\u03b1, \u0263-Synuclein, and interleukin-13 in patients with bladder cancer: A pilot study","volume":"2020","author":"Szyma\u0144ska","year":"2020","journal-title":"J Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.12659\/MSM.892927","article-title":"Identification of \u03b3-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry","volume":"20","author":"Zhao","year":"2014","journal-title":"Med Sci monitor"},{"key":"B50","article-title":"Expression of \u03b3-synuclein in bladder carcinoma: a possible marker for prognosis","volume":"36","author":"Chen","year":"2016","journal-title":"Anticancer Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"176","DOI":"10.21037\/tau-22-538","article-title":"Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer","volume":"12","author":"Ying","year":"2023","journal-title":"Trans Andrology Urology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2011.522","article-title":"Overexpression of DJ-1 and HSP90\u03b1, and loss of PTEN associated with invasive urothelial carcinoma of urinary bladder: Possible prognostic markers","volume":"3","author":"Lee","year":"2012","journal-title":"Oncol letters"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1587558\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:15:06Z","timestamp":1763702106000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1587558\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":52,"alternative-id":["10.3389\/fonc.2025.1587558"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1587558","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"article-number":"1587558"}}